This two-day course covers various issues and challenges in regulatory science for gene and cell-therapy medicinal products.

CPD approval by the Royal College of Pathologists.

Aimed at learners in a wide range of roles that regularly face challenges in production, testing and registration of advanced medicinal products (ATMPs), our course will: 

• Reveal up-to-date gene/cell therapy development, production technology and regulation
• Clarify the ethics, clinical trial design and commercial licensing issues

As a wide range of novel gene and/or cell therapies are developed in clinical and preclinical studies, the important question of how to deliver potentially beneficial therapies to patients is often neglected.

In this course we'll discuss the regulations required to help make future medicinal products safe and effective, which evolve alongside advances in science and technology.

Learners will be taught by experts at UCL, the Medicines and Healthcare products Regulatory Agency, including specialists who work to develop and deliver NIBSC standards, and the Cell and Gene Therapy Catapult.

Course structure and teaching

The course will be taught on Wednesday 2nd & Thursday 3rd July 2025.

Join 10 expert lectures, two panel discussions and access online learning materials including additional readings and web-based quizzes to help your understanding.